Fate Therapeutics, Inc. (FATE)
1.835
-0.02
(-0.81%)
USD |
NASDAQ |
Nov 06, 16:00
1.83
0.00 (0.00%)
After-Hours: 20:00
Fate Therapeutics Total Long Term Debt (Quarterly) : 69.38M for Sept. 30, 2026
Total Long Term Debt (Quarterly) Chart
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 69.38M |
| June 30, 2026 | 70.75M |
| March 31, 2026 | 72.04M |
| December 31, 2025 | 73.29M |
| September 30, 2025 | 74.49M |
| June 30, 2025 | 75.68M |
| March 31, 2025 | 76.78M |
| December 31, 2024 | 77.85M |
| September 30, 2024 | 92.08M |
| June 30, 2024 | 93.92M |
| March 31, 2024 | 95.67M |
| December 31, 2023 | 97.36M |
| September 30, 2023 | 98.98M |
| June 30, 2023 | 100.56M |
| March 31, 2023 | 102.07M |
| December 31, 2022 | 103.71M |
| September 30, 2022 | 105.16M |
| June 30, 2022 | 106.59M |
| March 31, 2022 | 107.94M |
| December 31, 2021 | 109.24M |
| September 30, 2021 | 104.36M |
| June 30, 2021 | 105.40M |
| March 31, 2021 | 106.51M |
| December 31, 2020 | 93.94M |
| September 30, 2020 | 83.16M |
| Date | Value |
|---|---|
| June 30, 2020 | 78.68M |
| March 31, 2020 | 73.83M |
| December 31, 2019 | 25.24M |
| September 30, 2019 | 39.60M |
| June 30, 2019 | 41.01M |
| March 31, 2019 | 41.42M |
| December 31, 2018 | 14.88M |
| September 30, 2018 | 14.86M |
| June 30, 2018 | 14.85M |
| March 31, 2018 | 14.83M |
| December 31, 2017 | 14.81M |
| September 30, 2017 | 14.79M |
| June 30, 2017 | 6.676M |
| March 31, 2017 | 8.701M |
| December 31, 2016 | 10.69M |
| September 30, 2016 | 12.64M |
| June 30, 2016 | 14.54M |
| March 31, 2016 | 16.40M |
| December 31, 2015 | 18.24M |
| September 30, 2015 | 19.13M |
| June 30, 2015 | 19.70M |
| March 31, 2015 | 19.67M |
| December 31, 2014 | 19.63M |
| September 30, 2014 | 10.00M |
| June 30, 2014 | 0.746M |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| AVITA Medical, Inc. | 47.13M |
| Agenus, Inc. | 271.09M |
| Amgen, Inc. | 54.01B |
| Anika Therapeutics, Inc. | 24.56M |
| BioCryst Pharmaceuticals, Inc. | 825.78M |